Phase IIb Study to Assess the Efficacy, Safety and Tolerability of Two Dosing Regimens of AllerT in Comparison to Placebo in Adult Subjects Allergic to Birch Pollen

Trial Profile

Phase IIb Study to Assess the Efficacy, Safety and Tolerability of Two Dosing Regimens of AllerT in Comparison to Placebo in Adult Subjects Allergic to Birch Pollen

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Birch pollen allergy immunotherapy-Anergis (Primary)
  • Indications Allergic rhinoconjunctivitis; Tree pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Anergis
  • Most Recent Events

    • 07 Jun 2016 Results will be presented at the 35th European Academy of Allergy and Clinical Immunology (EAACI) Congress, according to an Anergis media release.
    • 07 Jun 2016 Results published in an Anergis media release.
    • 07 Jun 2016 Detailed results published in the Journal of Allergy and Clinical Immunology, according to an Anergis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top